The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks down as investors await US inflation data

Fri, 10th Jun 2022 12:17

(Alliance News) - Stock prices in London were lower at midday on Friday with market focus squarely on the upcoming US consumer price index report at 1330 BST.

The FTSE 100 index was down 87.83 points, or 1.2%, at 7,388.48. The mid-cap FTSE 250 index was down 195.88 points, or 1.0%, at 19,879.21. The AIM All-Share index was down 4.48 points, or 0.5%, at 960.74.

The Cboe UK 100 index was down 1.2% at 736.04. The Cboe 250 was down 1.4% at 17,547.62, and the Cboe Small Companies was down 0.8% at 14,639.25.

In mainland Europe, the CAC 40 in Paris was down 1.5% and the DAX 40 in Frankfurt was down 1.6%.

New York was pointed to a mixed open, following steep loses on Thursday. The Dow Jones Industrial Average was called down 0.3% and the S&P 500 down 0.2%, but the Nasdaq Composite was pointed up 0.1%. The indices had closed down 1.3%, 2.4%, and 2.8% respectively on Thursday.

A hotter-than-expected inflation print is likely to hurry the Federal Reserve along on its path of aggressive monetary policy tightening, ahead of the US central bank's interest rate decision next week. Last month, the Fed enacted its first over 50-basis-point hike since May 2000.

Elevated levels of inflation have posed one of the biggest headaches so far for the Biden administration in Washington, as soaring prices take a toll on American households. The annual inflation rate remained close to a 40-year high in April, leaving consumers struggling to afford necessities including food, shelter and fuel.

On Thursday, the European Central Bank belatedly joined the global policy tightening shift, announcing the end of its bond-buying programme and signalling it will hike interest rates several times this year.

Nick Chatters, investment manager at Aegon Asset Management, commented: "US inflation today will be a key data point for the market this week. Yesterday, the ECB signalled a hawkish path of policy to come, as did the Fed earlier in the year, but today could give Powell and company a fright if inflation surprises to the upside yet again. To be clear, they are looking for 'clear and convincing evidence' that inflation in the US is going to start falling back from its eye watering level."

Economists at Lloyds Bank said they expect the headline annual inflation rate to continue to slow, to 8.2% in May from 8.3% in April and 8.5% in March.

The core rate of inflation is seen falling to 5.9% from 6.2% in April and 6.5% in March. They said risks for the headline figure are skewed to the upside, due to the recent rise in energy prices.

"Core inflation seems more likely to have declined but there will be considerable interest in whether services inflation is continuing to accelerate. That would be an indication that inflationary pressures are broadening out," Lloyds said. "Overall, the report is not expected to ease the pressure on the Federal Reserve to continue to raise interest rates."

The CME Fedwatch service suggests markets are putting a 92% chance on another half-point rise this month to 1.5%.

In the FTSE 100, GSK was up 0.5% after the drugmaker unveiled positive pivotal phase three data for its respiratory syncytial virus vaccine candidate AReSVi 006 for adults.

The RSV vaccine candidate showed statistically "significant and clinically meaningful efficacy" in adults aged 60 years and above, GSK explained.

GSK said interim analysis was reviewed by an Independent Data Monitoring Committee, and the primary endpoint was exceeded with no unexpected safety concerns observed.

In the FTSE 250 index, Apax Global was the best performer, up 9.0%, after it said the Apax X Fund has sold its controlling stake in MyCase to AffiniPay.

Apax Global Alpha is a limited partner in the X Fund; it allows investors access to a portfolio of private equity funds advised by London-based Apax Partners.

X Fund acquired MyCase, which provides legal practice management software and integrated payments to legal professionals, in 2020.

Apax Global Alpha said that the sale values its current look-through investment in MyCase at around EUR22.5 million. This represents an increase of approximately 48% compared to the last unaffected valuation and an uplift of around EUR7.3 million in the adjusted net asset value of Apax Global Alpha at March 31, it added.

Elsewhere in London, ProCook was down 40% at 47.10p. The kitchenware retailer said trading has been hurt by increasingly challenging market conditions, with customers affected by "exceptional pressures" on discretionary spending.

The stock listed on the London Main Market back in November at an initial public offering price of 145.00p so is down by two-thirds in six months.

For the fourth quarter, which ended April 3, ProCook said it was trading against "exceptionally strong comparatives" from the prior year, when it benefited from pent-up demand following the lifting of Covid-19 restrictions and the reopening of retail stores.

The retailer said like-for-like sales have weakened across all channels, in line with the wider kitchenware market, though revenue remains "significantly higher" than the comparative pre-Covid period in 2019.

ProCook now expects to deliver adjusted pretax profit of between GBP4 million to GBP6 million for financial 2023. It didn't provide its adjusted pretax profit figure for financial 2022. In the first half of financial 2022, the six months that ended October 21 last year, underlying pretax profit was GBP3.6 million.

The Bank of England said the UK's high street banks are no longer "too big to fail" after it completed its assessment of the the eight "major" lenders in the country.

In its Resolvability Assessment Framework, the UK central bank said shareholders and investors, and not taxpayers, are in line to "bear the costs" if any bank suffers a collapse.

"In 2007-08, the UK did not have a regime to enable resolving banks without the use of public money. This left two choices when some got into trouble: let banks fail and cause huge disruption or bail them out with taxpayers' money," the BoE said.

Now, however, the central bank said it now has a "robust" framework to deal with the fallout of a banking crisis. The eight banks to take part in the assessment were HSBC, Barclays, NatWest, Lloyds Banking, Standard Chartered, Banco Santander's UK operations, Virgin Money UK and Nationwide Building Society.

HSBC was down 1.2%, Barclays down 0.9%, NatWest down 1.0%, Lloyds down 0.9%, Standard Chartered down 1.0%, and VMUK down 2.7%.

Banco Santander was down 4.1% in Madrid.

The pound was quoted at USD1.2450 at midday on Friday, down from USD1.2536 at the London equities close Thursday.

The euro was priced at USD1.0608, down from USD1.0657. Against the yen, the dollar was trading at JPY133.76 in London, lower against JPY134.16.

Brent oil was quoted at USD124.07 a barrel Friday at midday, up from USD123.37 late Thursday. Gold stood at USD1,843.75 an ounce, up slightly from USD1,842.36.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.